Resmed (Germany) Performance
| RMEA Stock | EUR 20.20 0.40 2.02% |
The company holds a Beta of -0.0359, which implies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Resmed are expected to decrease at a much lower rate. During the bear market, Resmed is likely to outperform the market. At this point, Resmed Inc DRC has a negative expected return of -0.0751%. Please make sure to check Resmed's maximum drawdown, skewness, daily balance of power, as well as the relationship between the potential upside and kurtosis , to decide if Resmed Inc DRC performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Resmed Inc DRC has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable technical and fundamental indicators, Resmed is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 295.3 M | |
| Total Cashflows From Investing Activities | -229.9 M |
Resmed |
Resmed Relative Risk vs. Return Landscape
If you would invest 2,135 in Resmed Inc DRC on December 22, 2024 and sell it today you would lose (115.00) from holding Resmed Inc DRC or give up 5.39% of portfolio value over 90 days. Resmed Inc DRC is producing return of less than zero assuming 1.8624% volatility of returns over the 90 days investment horizon. Simply put, 16% of all stocks have less volatile historical return distribution than Resmed, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Resmed Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Resmed's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Resmed Inc DRC, and traders can use it to determine the average amount a Resmed's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0403
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | RMEA |
Estimated Market Risk
| 1.86 actual daily | 16 84% of assets are more volatile |
Expected Return
| -0.08 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.04 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Resmed is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Resmed by adding Resmed to a well-diversified portfolio.
Resmed Fundamentals Growth
Resmed Stock prices reflect investors' perceptions of the future prospects and financial health of Resmed, and Resmed fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Resmed Stock performance.
| Return On Equity | 0.24 | |||
| Return On Asset | 0.12 | |||
| Profit Margin | 0.22 % | |||
| Operating Margin | 0.28 % | |||
| Current Valuation | 31.38 B | |||
| Shares Outstanding | 1.47 B | |||
| Price To Earning | 41.55 X | |||
| Price To Book | 9.35 X | |||
| Price To Sales | 8.00 X | |||
| Revenue | 3.58 B | |||
| EBITDA | 1.19 B | |||
| Cash And Equivalents | 147.13 M | |||
| Cash Per Share | 0.10 X | |||
| Total Debt | 765.33 M | |||
| Debt To Equity | 61.30 % | |||
| Book Value Per Share | 6.36 X | |||
| Cash Flow From Operations | 351.15 M | |||
| Earnings Per Share | 0.51 X | |||
| Total Asset | 5.1 B | |||
About Resmed Performance
By analyzing Resmed's fundamental ratios, stakeholders can gain valuable insights into Resmed's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Resmed has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Resmed has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California. RESMED CUFS10 is traded on Frankfurt Stock Exchange in Germany.Things to note about Resmed Inc DRC performance evaluation
Checking the ongoing alerts about Resmed for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Resmed Inc DRC help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Resmed Inc DRC generated a negative expected return over the last 90 days | |
| The company has €765.33 Million in debt which may indicate that it relies heavily on debt financing |
- Analyzing Resmed's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Resmed's stock is overvalued or undervalued compared to its peers.
- Examining Resmed's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Resmed's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Resmed's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Resmed's stock. These opinions can provide insight into Resmed's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Resmed Stock analysis
When running Resmed's price analysis, check to measure Resmed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Resmed is operating at the current time. Most of Resmed's value examination focuses on studying past and present price action to predict the probability of Resmed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Resmed's price. Additionally, you may evaluate how the addition of Resmed to your portfolios can decrease your overall portfolio volatility.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Stocks Directory Find actively traded stocks across global markets |